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and collagen expression in dermal fibroblasts
from regenerative FOXN1 deficient (nude) mice
Barbara Gawronska-Kozak1,2* and Heather Kirk-Ballard1Abstract
Background: Cyclosporin A (CsA), an immunosuppressive agent modifies the wound healing process through an
influence on extracellular matrix metabolism. We have compared the effects of CsA on dermal fibroblasts from
nude (FOXN1 deficient) mice, a genetic model of skin scarless healing, and from control (C57BL/6 J (B6) mice to
evaluate metabolic pathways that appear to have important roles in the process of scarless healing/regeneration.
Results: High levels of matrix metalloproteinases (MMPs) and collagen III expression in dermal fibroblasts from
nude (regenerative) mice were down-regulated by CsA treatment to the levels observed in dermal fibroblasts from
B6 (non-regenerative) mice. In contrast, dermal fibroblasts from control mice respond to CsA treatment with a
minor reduction of Mmps mRNA and 2.5-fold increase expression of collagen I mRNA. An in vitro migratory assay
revealed that CsA treatment profoundly delayed the migratory behavior of dermal fibroblasts from both nude and
control mice.
Conclusion: The data suggest that by alternation of the accumulation of extracellular matrix components CsA
treatment stimulates the transition from a scarless to a scar healing.
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Cyclosporin A (CsA) is a widely used immunosuppres-
sant for the treatment of autoimmune disorders and to
prevent rejection after organ transplantation. However,
CsA also causes significant side effects relevant to the
healing process. Gingival overgrowth is one of the
reported side-effects in 8-70% of CsA- treated patients [1].
This over-growth is characterized by an accumulation of
extracellular matrix within the gingival tissue, particularly
the collagenous component [1].
Importantly, mammals which are generally considered
not to have the capacity for regeneration, display regenera-
tive/scar-free healing in injured gingiva that can be
regarded in this respect as a privileged tissue [2,3]. The
regenerative capacity of gingival tissue has been attributed* Correspondence: b.kozak@pan.olsztyn.pl
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use, distribution, and reproduction in any medto the high levels of collagen and matrix metalloproteinases
(MMPs) expression [3,4]. CsA treatment alters collagen
turnover in gingival tissue through changes in its capacity
to synthesize, degrade and remodel collagens [5,6]. Accor-
dingly, the alterations in metabolism of collagen have been
shown to occur in both human gingival overgrowth tissue
and in in vitro models treated with CsA [1,5-7]. Collagen
degradation appears to be modulated through the action of
CsA on the MMPs-dependent and MMPs-independent
pathways [8]. The gingival fibroblasts from CsA treated
patients and animals showed reduced expression of
MMP-1 and MMP-3, consistent with conditions that
increase collagen accumulation [9,10]. Similarly, MMPs
synthesis was decreased in CsA-treated cultured gingival
fibroblasts [11].
The anti-regenerative action of CsA treatment was even
more evident in the studies by Sicard et al., showing that
CsA treatment blocks forelimb regeneration in amphibians,
the masters of regenerative potential, in a dose-dependent
fashion [12].nsee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly cited.
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(nude) mice are one of the few examples among
mammals that exhibit scarless wound healing. Wounds
in both: skin and 2 mm holes in their ears heal without
scars by a process that resembles regeneration [13-16].
The post-injured skin of nude mice is characterized by
lack of scar, low levels of collagen content, and higher
levels of MMP-9 and MMP-13 expression than
observed in wild type mice [14,15]. Since nude mice
are immunodeficient, in our previous study we tested
the hypothesis that the lack of T lymphocytes
predisposes them to regeneration/scar-free healing.
Accordingly, when we treated control animals with
CsA to reduce immune response at post-injured skin
area, although T lymphocytes levels were reduced,
there was no decrease in scarring of CsA-treated
mice. The scar tissues of CsA-treated animals appeared
similar or even more prominent (data not shown) than in
control untreated mice [14]. Moreover, we subsequently
showed that dermal fibroblasts from regenerative (nude)
mice expressed higher levels of type I and III collagens,
Mmp-9 and Mmp-13 mRNA expression and higher MMP
enzyme activity than wild type controls, similar to
cultured gingival fibroblasts [16]. High levels of MMPs
and collagen expression detected in cultured gingival
fibroblasts were attributable to scarless healing of gingival
tissue, whereas their inhibition by CsA treatment was
associated with gingival overgrowth [3,4,9,10].
These observations have led us to the present study
in which we test the hypothesis that CsA treatment
affects genes of collagens and MMPs more strongly
in tissues from mice with regenerative abilities than
from non-regenerative wild type mice.
Results
Differences in immunophenotype between dermal
fibroblasts from nude (regenerative) and B6 (non-
regenerative) strains of mice
Flow cytometric analysis was used to evaluate the
phenotypic differences between freshly isolated/non-
cultured dermal fibroblasts from the skin of nude (Hsd:
Athymic Nude-Foxn1nu) and C57BL/6 J (B6) mice
(Figure 1). Cells were examined for the expression of
stem cell markers: Sca-1, CD117, Oct3/4 and stromal cell
markers: CD90, CD73, CD44. The analysis demonstrated
that a high percentage of nude dermal fibroblasts
expressed stem cell marker CD117 (22.27% ± 1.27) and
Oct3/4 (3.88% ± 0.42), whereas the frequency of B6
dermal fibroblasts were 11.36% (±2.22) of CD117 and did
not express Oct3/4 (Figure 1). The frequency of the
stromal-associated surface antigens for CD90 was 27.38%
(±2.67) and 37.73% (±1.12) for CD44 in nude dermal
fibroblasts. The frequency of expression in B6 dermal
fibroblasts was much lower for CD90 (11.53% ± 1.18) andCD44 (17.82% ± 7.0). There were no differences in the fre-
quency of Sca-1 and CD73 expression between nude and
B6 dermal fibroblasts.
Effect of CsA on Mmps mRNA expression
Dermal fibroblasts isolated from regenerative (nude - Hsd:
Athymic Nude-Foxn1nu) and from control (C57BL/6 J
(B6) strains of mice were cultured under the same
conditions (seeding density, collagen coated dishes). Quan-
titative RT-PCR analysis showed that Mmp-3, Mmp-9
and Mmp-13 mRNA levels were 3.5; 1.5- and 4-fold
higher in nude than B6 dermal fibroblasts (Figure 2).
To evaluate the effect of CsA on MMPs expression,
cultured dermal fibroblasts from nude and wild type
mice were treated for 24 hours with increasing doses
of CsA (0-10000 ng/ml). CsA down regulated Mmp-3,
Mmp-9 and Mmp-13 mRNA expression in cultured
nude fibroblasts at a concentration of 1000 ng/ml.
The largest suppressive effect of CsA was observed
for Mmp-13 mRNA in which levels were suppressed
50% in nude fibroblasts at a low (10 ng/ml) dose of
CsA. In contrast, Mmps mRNA levels in dermal
fibroblasts from wild type mice were not reduced by CsA
treatment until the dose of CsA (10000 ng/ml) was 1000-
fold higher (MMP-9 (p < 0.01) and MMP-13 (p < 0.05)
(Figure 2).
CsA affects PKC signaling
In vivo studies by Watanabe et al., showed that CsA
treated FOXN1 deficient (nude) mice overcome some
aspects of FOXN1 deficiency, that is, they displayed hair
re-growth [17]. In a follow up study they showed that
this phenomenon may involve PKC, whose high activity
in nude skin is suppressed by CsA treatment [18]. Since
CsA reduces levels of Mmps in nude dermal fibroblasts
to the levels expressed by wild type dermal fibroblasts
(see Figure 2) we reasoned that PKC can be a pathway
through which CsA regulates MMPs expression. Additio-
nally, our hypothesis was supported by studies demonstrat-
ing that the PKC pathway controls MMPs expression
in fibroblasts [19]. To examine the effect of CsA on the
expression of PKC signaling we used Western blotting
techniques (Figure 3). We compared PKC levels in primary
cultures of nude and B6 dermal fibroblasts treated with
increased doses of CsA. As shown in Figure 3A, levels
of PKC α, δ and ε in wild dermal fibroblasts were not
affected by CsA treatment. In contrast, in nude dermal
fibroblasts a gradual reduction in PKC δ expression oc-
curred with an increasing dose of CsA, whereas PKCα
expression increased as CsA concentration raises
(Figure 3A). CsA treatment slightly reduced the expres-
sion of PKCε in nude dermal fibroblasts (Figure 3A). To
determine whether CsA treatment affects PKC phosphor-
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Figure 1 Immunophenotypic characterization of freshly isolated dermal fibroblasts from nude and B6 mice by flow cytometric
analysis. Cells were labeled with phycoerythrine-conjugated antibodies against Sca-1, CD117, Oct3/4, CD90, CD73 and CD44. (A) The data (% of
labeled cells) represent the mean of three experiments. Each experiment consisted of a pool of cells collected from three animals. Asterisks
indicate significant differences between nude and B6 dermal fibroblasts (** p < 0.01; ***p < 0.001). (B) Representative flow cytometric analysis of
dermal fibroblasts. The percentage of cells staining positive is indicated on each panel.
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vation of PKC was measured in total cell lysates using
anti-phospho-PKC (pan) antibodies. CsA treatment
reduced phospho-PKC expression at the higher doses in
wild type fibroblasts, whereas in nude dermal fibroblasts
the reduction of pPKC pan expression in CsA treated
cells was greater and was observed even at the lower
doses (Figure 3B). Nude dermal fibroblasts treated with
CsA lost higher molecular weight band and showed a
gradual reduction in the intensity of the second band.
Untreated nude cultures were similar to control and
CsA-treated wild type fibroblasts by displaying two
bands on the blot, which correspond to the blotsprovided by antibody supplier (Cell Signaling Technology)
(Figure 3B).
Effect of CsA on type I and III collagens mRNA expression
To determine the effects of CsA on collagens we first
determined the basal (control) levels of collagen I and
collagen III mRNA expression in untreated fibroblasts
(Figure 4 A, B and C at 0 CsA). Cultured dermal
fibroblasts from nude mice showed 8.5 and 5 fold higher
collagen I and collagen III (respectively) mRNA expres-
sion than those from wild type mice (Figure 4A, B and
C). CsA treatment increased expression of collagen I





























































Figure 2 Cyclosporin A decreases Mmps mRNA expression in
dermal fibroblasts. Quantitative RT-PCR determination of Mmps
mRNA levels was analyzed in cultured CsA-treated dermal fibroblasts
from nude and wild-type mice. Expression of Mmps mRNA was
normalized to levels of Hprt1 mRNA. Triplicate assays were used and
experiment was repeated three times each time using dermal
fibroblasts isolated from different set of animals (n = 9). Error bars
represent SEM; *p < 0.05; **p < 0.01; ***p < 0.001 (nude dermal
fibroblasts) and #p < 0.05, ##p < 0.01 (wild type dermal fibroblasts)
calculated relative to respective controls, untreated cells (0 ng/ml CsA).
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collagen expression in nude dermal fibroblasts (Figure 4B).
In contrast to collagen I, collagen III mRNA expression in
wild type dermal fibroblasts was unaffected by CsA treat-
ment, whereas CsA-treated nude dermal fibroblasts
showed a dose dependent reduction in collagen III mRNAexpression between 100 ng/ml (p < 0,05) and 1000 ng/ml
(p < 0.001) of CsA (Figure 4C).
CsA delays dermal fibroblasts migration in vitro
Since CsA suppresses the elevated expression of MMPs
and collagen in nude dermal fibroblasts we asked whether
CsA influences the migratory behavior of dermal fibro-
blasts. We utilized an established in vitro wound migration
assay [20]. Prior to making the wound, monolayer, conflu-
ent cultures of dermal fibroblasts were pre-treated with
mitomycin C for 3 hours to suppress further proliferation
of the cells. Then, the wounds (scratch) were made and the
distance between wounded edges was measured at 0, 6, 12,
24 and 36 post-wounded hours.
Overall the data showed that CsA significantly delayed
the migration of fibroblasts from both nude and wild
type animals (Figures 5, 6, 7). The migratory delay in
CsA-treated cells was observed at the 6, 12 and 24 h
time-period (Figures 5, 6) with doses of either 100 or
1000 ng/ml CsA (Figure 5).
Wound closure in untreated dermal fibroblasts from
both nude and wild type mice occurred in about 24 h
[Figure 5; Figure 7E (nude) and F (B6)], whereas open
wounds in CsA-treated fibroblasts were still present
[Figure 5; Figure 7C (nude) and D (B6)]. CsA retar-
ded wound closure to a similar extent in both nude
and B6 dermal fibroblasts (compare Figure 7A and B;
Figure 7C and D).
Discussion
In the present study we have assessed the effects of CsA
on dermal fibroblasts from nude (FOXN1 deficient)
mice, animals that are capable of healing skin injuries and
punched ears in a scar-free/regenerative fashion. Our data
show that CsA alters expression of collagens and Mmps
synthesis and retards the migration of dermal fibroblasts,
changes expected to affect the structure of the ECM.
Additionally, the data suggest that CsA particularly affects
tissues which are privileged for regenerative features,
that is, skin of nude mice (present data), forelimb in
amphibians [12] and gingival tissue [2].
Immunophenotypic characterization of dermal fibroblasts
showed substantial differences between nude (regenerative)
and B6 (non-regenerative) mice. Dermal fibroblasts from
nude mice are characterized by high levels of stem cells
markers expression (CD117 and Oct3/4) that are low
(CD117) or absent (Oct3/4) in non-regenerative B6 mice.
The expression of stem cell markers in nude dermal
fibroblasts may indicate that nude mice possess features of
embryonic development in adulthood that are absent in B6
mice and may explain their ability for scarless skin healing.
Interestingly, the presence of embryonic and fetal molecu-
lar, metabolic and cellular features retained during adult-
hood was observed in another regenerative strain of mice,
PKC
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Figure 3 Cyclosporin A reduces protein kinase C (PKC) signaling in nude dermal fibroblasts. Primary dermal fibroblast from nude and wild
type mice were treated with varying doses of CsA (0.1-1000 ng/ml) for 24 h. Cell lysates was harvested and 40 microgram of total protein per
sample was separated on 12% electrophoresis gel. The levels of α, β, ε PKC and phosphorylated-PKC (pan) were determined by immunobloting
with specific antibodies. All samples were immunoblotted for ß-actin to assess variation in protein loading. The levels of α, β, ε PKCs (A) and
phosphorylated-PKC (B) are shown.
Gawronska-Kozak and Kirk-Ballard Fibrogenesis & Tissue Repair 2013, 6:7 Page 5 of 11
http://www.fibrogenesis.com/content/6/1/7MRL [21]. However, from the another point of view, the
sole existence of mesenchymal stem cells in adult tissues is
not sufficient for regeneration to happen as we showed for
mouse ear hole closure [13]. External ears of regenerative
and non-regenerative strains of mice contain a population
of mesenchymal stem cells (EMSC - ear mesenchymal stem
cells) that are capable of differentiating into 4 lineages
in vitro. Nevertheless, only holes in the ears of nude mice
heal with the features of the regenerative process [13].
Regardless whether the stem cell features of nude dermal
fibroblasts can account for scarless skin healing, the profiles
of these stem cell markers underline the existence of
immunophenotype differences between nude and B6
dermal fibroblasts. Moreover, dermal fibroblasts derived
from FOXN1 deficient (nude) mice produce higher levels
of Mmp-3, -9 and 13 than B6 wild type. CsA treatment
reduced the levels of Mmps expression in nude dermal
fibroblasts to the levels observed in B6 wild type (control),
but had no effect on Mmps expression in B6 wild type
mice. Our data are consistent with results obtained in other
studies on the effect of CsA on gingival fibroblasts. The
gingival fibroblasts from CsA treated patients and animals
showed reduced expression of MMP-1 and MMP-3 [9,10].
Similarly, CsA treated cultured gingival fibroblasts had a
decrease in MMPs synthesis [11,22]. The action of CsA
among published studies has varied from suppressive (as
described above and in our studies) to stimulative (increase
in MMPs and collagen [7]). The observed discrepancies
could be due to in vivo vs in vitro studies. Additionally, the
type, origin and state of development of the cells (in vitrostudy) and individual differences among subjects (in vivo
study) could determine the course of CsA action. The most
profound differences in CsA action was observed between
gingival and dermal fibroblasts. The synthesis of collagen
Iα1 was stimulated in keratinocytes co-cultured with
gingival fibroblasts treated with CsA [23] and suppressed in
cultured dermal fibroblasts [24]. Similarly, our studies
showed that CsA treatment reduced collagen III expression
in nude fibroblasts, but expression was unchanged in B6.
Simultaneously, CsA increased collagen I in B6 but had no
influence on collagen I expression in nude mice (see
Figure 4). Higher and sustained levels of collagen III expres-
sion characterize scar-free skin healing in mammalian
fetuses that is observed during first two trimesters of gesta-
tion [25]. Fetuses from last trimester of gestation, as well
adult mammals, heal skin injuries with scar formation
which is accompanied by higher levels of collagen I expres-
sion in postinjured area. Changes from higher to lower ratio
of collagen III to collagen I accumulation in postinjured
skin tissues is one of the indicators of transition between
scar-free to scar-forming healing in mammalian fetuses
[25]. Our data indicate that CsA treatment (decrease levels
of collagen III in nude/regenerative fibroblasts and increase
levels of collagen I in control fibroblasts) contributes to
the accumulation of extracellular matrix components
that can cause the switch from scar-free to scar forming
healing. Accordingly, we propose the concept that
CsA may interfere in regenerative (scar-free) healing




















































Figure 4 CsA modulates the expression of collagen I (A and B)
and collagen III (C) mRNA in cultured dermal fibroblasts.
Quantitative RT-PCR determination of collagen I and III mRNA levels
was assessed in cultured CsA treated dermal fibroblasts from nude and
wild-type mice. Expression of collagens mRNA was normalized to
levels of Hprt1 mRNA in the reaction. The means and standard errors
are shown from three experiments, each performed in triplicate (n = 9);















































Figure 5 Cyclosporin A delays dermal fibroblasts wound
migration in vitro. Wounded, monolayered dermal fibroblasts from
nude (A) and wild type (B) mice were cultured for 36 hours with
CsA at concentrations of 100 ng/ml or 1000 ng/ml. Migration was
expressed as a percentage of distance between post-wounded
edges of monolayered dermal fibroblasts. Triplicate wells were used
and the experiment was repeated three times (n = 9). Error bars
represent SEM; ***p value <0.001 calculated from the differences
between control and CsA treated cultures at 6, 12 and 24 h.
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observed in gingival tissue, seems to be beneficiary for
unhealing skin wounds [26,27], that is, CsA treatment
not only reduced inflammation, but also promoted skin
healing in healing-resistant lesions [26,27].
Generally the outcome of the healing process is attri-
butable, among others features, to the MMP/TIMP ratio
and the collagen synthesis/degradation rate. Regularhealing is characterized by equilibrium between MMP
and TIMP which is essential during wound repair [28].
A decrease in MMP-to-TIMP (ie. 1:2) may contribute to
increased synthesis and deposition of collagen, leading
to pathological (overgrowth) scar formation [29]. On the
other hand, an increased MMP/TIMP ratio due to high
levels of MMPs and low levels of TIMPs accompany
delayed wound healing [28,30]. Similar dynamic changes
in MMPs and TIMPs expression was observed during
wound healing in diabetic humans and animal models
[31,32]. However, increased MMPs expression has also
been observed during perfect, scarless healing in
mammalian fetuses, gingival tissue and skin wounds
in nude mice [3,15,16,33,34]. Thus, changing the balance
between MMP/TIMP and collagens synthesis/degradation
by CsA treatment can influence the outcome of the
healing process.
Accordingly, we propose that CsA treatment may
modulate the outcome of the healing process (Figure 8).





Figure 6 CsA treatment retards dermal fibroblasts wound healing in vitro. Monolayered dermal fibroblasts were wounded and allowed to
heal in the absence (B, D, F) or presence (C, E, G) of CsA. Representative images from nude dermal fibroblasts cultures were taken at 0 (A), 6 (B, C),
12 (D, E) and 24 (F, G) hours after scratch. White arrows indicate the distance between post-wounded edges of monolayered fibroblasts.
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expression and stimulate collagen synthesis to promote
healing. For scarless healing, requiring higher levels of
MMPs and lower levels of collagen, CsA treatment results
in the reduction of MMPs and collagen to the levels
measured in normal, scar-present healing. For regular
wound healing with scar formation, normally observed ata MMP/TIMP ratio 1:1, CsA treatment will shift the ratio
towards 1:2 and increasing collagen accumulation charac-
teristic of scar overgrowths. Although the mechanism of
CsA action is still unclear, our intention is to turn atten-
tion towards the beneficial effects of CsA in treating dia-
betic skin ulcers and to the undesirable effects of CsA on




Figure 7 There are no differences of CsA effect on in vitro wound healing between dermal fibroblasts from regenerative (nude) and
non-regenerative (B6) mice. Wounded dermal fibroblasts from nude (A, C) and B6 (B, D) were cultured in the presence of CsA. The images
were taken at 6 (A and B) and at 24 hour (C, D) after treatment. Non-treated dermal fibroblasts at 24 hour: (E) nude, (F) B6.
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We have demonstrated that CsA treatment down-
regulates the expression of MMPs and collagen III
expression in dermal fibroblasts from regenerative
(nude) mice to the levels observed in non-regenerative
(B6) mice. Moreover, an in vitro migratory assay
revealed that CsA treatment profoundly delays the
migratory behavior of dermal fibroblasts from both nude
and control mice. The data suggest that CsA particularly
affects tissues privileged for regeneration and stimulates
the transition from scarless to scar healing.
Methods
Isolation and culture of dermal fibroblasts
Skin tissues were collected from Hsd: Athymic Nude-
Foxn1nu (n = 9) (Harlan Sprague–Dawley, Indianopolis,
IN) and C57BL/6 J (n = 9) (B6; Jackson Laboratory (Bar
Harbor, ME) mice during three independent experiments.
Tissues were minced and digested with collagenase class I
(2 mg/ml; Worthington Biochemical Corp., Freehold, NJ)
in a shaking water bath at 37°C for 1 hour. Dissociated
dermal fibroblasts were filtered through a 100 μm cellstrainer (Becton Dickinson Labware, NJ) and centrifuged
at 360xg for 5 min. Pelleted cells were resuspended for
1 min in red blood cell lysing buffer (Sigma Co. St. Louis,
MO) and were centrifuged at 360 × g for 5 min to remove
erythrocyte contamination. Cells were stored in liquid
nitrogen at concentration 2×106/vial.
Thawed dermal fibroblasts (p = 0) from nude and wild
type mice were plated on collagen I coated 6-well plates
at density 0.2 x106 cells per well (p = 1) in Dulbecco’s
Modified Eagle Medium (DMEM/F12; Life Technologies,
New York, NY) supplemented with 15% fetal bovine
serum (FBS - Life Technologies, New York, NY) and
antibiotics. Dermal fibroblasts at 80-90% confluency were
washed with DMEM/F12 media without FBS and then
incubated for 24 hours in DMEM/F12 media with 5% FBS
and different concentrations of cyclosporin A (CsA Sigma
c1832). The range of CsA treatment doses were chosen
based on in vitro [10] and in vivo [9] data from
human [26] and animal [9] studies. Triplicate wells
were used per treatment and the experiment was
repeated three times each time using cells collected
from different set of animals.
Figure 8 A model to illustrate how CsA treatment can
modulate outcome of the healing process. CsA contributes to
extracellular matrix accumulation through reduction of MMPs
expression (MMP/TIMP balance) and modulation of collagen
accumulation. In non-healing wounds reducing MMPs expression by
CsA treatment promotes a healing process that resembles scarless
healing. Scarless healing (e.g. gingival tissue and nude skin) is
characterized by a modest elevation of the MMP/TIMP ratio which is
shifted by CsA treatment to a balanced MMP/TIMP ratio (1:1) and
results in healing with scar formation. Further suppression of the MMP/
TIMP and increasing collagen content progresses from regular wound
healing with scar formation to the overgrowth of scar tissues.
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these studies have been approved by the Institutional
Animal Care and Use Committee at the Pennington
Biomedical Research Center.
Flow cytometry assay
Additional groups of Hsd: Athymic Nude-Foxn1nu (n = 9)
(Harlan Sprague–Dawley, Indianopolis,IN) and C57BL/6 J
(n = 9) (B6; Jackson Laboratory (Bar Harbor, ME) mice
were used to characterize the immunophenotype of
dermal fibroblasts isolated from the skin. Cells were
collected from the skin according to the isolation proce-
dure described above. Freshly isolated cells were
incubated with phycoerythrin-conjugated antiSca-1,
antiCD117, antiCD90, antiCD73 and antiCD44 antibodies
(BD Pharmingen, San Diego, CA) as previously described
[35]. For immunophynotyping with Oct3/4 antibodies
(R&D Systems, Inc.) staining was performed according to
intracellular staining procedure recommended by antibody
supplier. The flow cytometry assay was performed using a
FACScan flow cytometer (Becton Dickinson, San Jose, CA)
and data were analyzed with a Macintosh G5 workstation
(Apple Computer, Cupertino, CA), which contains Cell-
quest graphics software (Becton Dickinson, San Jose, CA)for data acquisition and analysis. FACS plots and data are
representative of three separate experiments.
RNA isolation and quantitative RT-PCR
Total RNA was extracted using Trizol (Invitrogen,
Carlsbad, CA) and column-purified with RNeasy and
RNase-Free DNase kits (Qiagen, Valencia, CA). cDNA
synthesis was performed with 500 ng of total RNA
using the High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA). Endogenous mRNA
levels for: Mmp-3, Mmp-9, Mmp-13, α1 chain of type
I collagen (col1a1), α1 chain of type III collagen
(col3a1) and the housekeeping gene hypoxanthine
phosphoribosyltransferase 1 (Hprt1) were measured
with Applied Biosystems TaqmanW Gene Expression Assays
(Applied Biosystems, Foster City, CA). Reactions were
performed in MicroAmp Optic 384-well Reaction Plates
(Applied Biosystems) using the ABI Prism 7900 Sequence
Detection System (Perkin Elmer, Boston, MA) under the
following incubation conditions: 2 min at 48°C, 10 min at
95°C, 40 cycles of 15 s at 95°C and 1 min at 60°C. Each run
included a standard curve with aliquots from a RNA pool
isolated from skin tissues, a non-template control, and
minus reverse transcriptase control that were analyzed
in duplicate. Expression levels for each gene estimated
from the standard curve were normalized to Hprt1
and multiplied by 10.
Protein isolation and western blot analysis
Total cell lysates were prepared by adding 400 μl of RIPA
buffer containing protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO) and phosphatase inhibitor cocktails
I and II (Sigma-Aldrich, St. Louis, MO). Total protein
(40 μg) was separated on 12% SDS–polyacrylamide gels
and transferred onto PVDF membranes (Millipore,
Billerica, MA). The blots were then incubated with anti-
bodies against PKCα, ß, ε (Cell Signaling Technology),
phospho-protein kinase C antibody that detect PKCα,
ß I, ß II, δ, ε and η isoforms (PKC (pan) (ßII Ser660;
Cell Signaling Technology) and against β actin
(Abcam Inc.). Bands were visualized using the Odyssey
imaging system (LI-COR Bioscience, Lincoln, NB) with
fluorescent (IRDye800TM or Alexa FluorW 680) labeled
secondary antibodies according to manufacturer’s protocol.
Wound migration assay
Dermal fibroblasts from nude and wild type mice at
passage 1 were used for wound migration assay. To control
cells proliferation capacity confluent dermal fibroblasts
were pre-treated for 3 hours with mitomycin (10 μg/ml).
Next, cells were washed with DMEM/F12 with 5% of FBS.
To evaluate wound migration, confluent dermal fibro-
blast cultures were scraped throughout middle part of
the entire 35 mm plate with the aid of 200 μl pipette
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containing DMEM/F12 with two different concentrations
of cyclosporin A: 100 ng/ml or 1000 ng/ml. Cultures
were photographed at 6, 12, 24 and 36 hours after
wounding. Distance between post-wounded edges was
visualized with camera mounted microscope and
measured with Metamorph software. Triplicate wells
were used per treatment and the experiment was
repeated three times.
Statistical analysis
All data are expressed as a mean ± SEM. Student’s t test
(Microsoft Excel) was used for analyzing differences
between experimental groups as indicated in the figure
legends. A value of p < 0.05 was considered significant.
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